Business Wire

Celltrion Healthcare Showcases Promising Preliminary Results for New Subcutaneous Formulation of CT-P13 (biosimilar infliximab) in Patients with Rheumatoid Arthritis

Del

New data presented at the Annual European Congress of Rheumatology (EULAR 2018) show that the subcutaneous (SC) formulation of CT-P13 is comparable in terms of efficacy and safety with the intravenous (IV) formulation of CT-P13 for the treatment of patients with rheumatoid arthritis (RA) up to week 30. The results indicate that CT-P13 SC could be a future alternative infliximab treatment.1

The objective of the randomised, controlled phase I/III study was to evaluate efficacy, pharmacokinetic (PK) properties and the safety profile of CT-P13 SC over the first 30 weeks of treatment and to find the optimal dose of CT-P13 SC.

In the study, patients were randomly assigned into four cohorts; one group receiving CT-P13 IV and the other three receiving different doses of CT-P13 SC (90mg/120mg/180mg) bi-weekly. The initial 30-week results from the study showed comparable efficacy of CT-P13 SC to CT-P13 IV regardless of the route of administration or dosage with similar DAS28 and ACR20 scores - standardised disease improvement measurements for rheumatoid arthritis used to measure disease activity and disease improvement respectively. The safety profiles in CT-P13 SC cohorts were comparable to CT-P13 IV.1

Professor Rene Westhovens, Rheumatologist at the University Hospitals KU Leuven, Belgium said: “These preliminary results are encouraging as they show that CT-P13 SC is safe and has comparable efficacy to the well-established intravenous version. This new injection formulation of infliximab would give patients the opportunity to self-inject, saving their time and giving them more autonomy.”

Mr Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare said, “At Celltrion Healthcare, our aim is to provide the best possible treatment options for patients and physicians. While the treatment of intravenous CT-P13, an infliximab biosimilar, is effective and well-tolerated, a new SC formulation would provide added patient convenience. Subsequently, based on the positive week 30 results presented today, we are planning to launch CT-P13 SC next year if approved as part of our ‘twin-track’ strategy to create more choice and synergy across the healthcare system.”

--- Ends---

Notes to editors:

About rheumatoid arthritis

In Europe, more than 2.9 million people have rheumatoid arthritis (RA), many of whom are of working age. On average, every third person with RA becomes work disabled and up to 40 per cent leave work completely within 5 years of diagnosis.2 Although there is no cure for RA, there are many treatments that can reduce inflammation and ease pain. As with all rheumatic diseases early diagnosis and intervention is key.

About CT-P13 (biosimilar infliximab)

CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 87 countries (as of May 2018) including the US, Canada, Japan and throughout Europe.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/

1 Westhovens et al. Novel formulation of CT-P13 for subcutaneous administration in patients with rheumatoid arthritis: Initial results from a phase I/III randomized controlled trial. Annual European Congress of Rheumatology (EULAR). 2018. THU0191

2 NRAS, European Fit for Work Report. Available at www.nras.org.uk/european-fit-for-work-report.

Contact information

Hanover Communications
Suru Douglas
sdouglas@hanovercomms.com
+44 203 817 6586
or
Georgia Featherston
gfeatherston@hanovercomms.com
+44 203 817 6718

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Blommer Chocolate to Be Acquired by Fuji Oil Holding19.11.2018 09:03Pressemelding

The Blommer Chocolate Company, the largest ingredient chocolate manufacturer in North America and third largest in the world, announced that it has entered into an agreement to be acquired by Fuji Oil Holding, Inc., a global leader in oil and fat ingredients serving the food industry. The sale includes all Blommer business entities, including its four manufacturing operations in North America and one in Shanghai. Blommer is a private, family-owned company; Fuji Oil is publicly traded on the Tokyo Stock Exchange. “For nearly 80 years, our family business has grown to become a major ingredients supplier to most of the iconic brands across a wide variety of food categories,” said Peter Blommer, CEO and third-generation family member. “This is a landmark event in the proud history of Blommer Chocolate Company and begins an exciting new chapter as we look forward to joining a highly respected global leader in Fuji Oil. Our companies share common values and a deep commitment to product quali

GSMA Announces New Speakers for Mobile 360 Series – MENA19.11.2018 09:00Pressemelding

The GSMA today announced a number of additional high-profile speakers for its Mobile 360 Series – MENA (Middle East and North Africa) conference taking place on the 26-27 November 2018 in Dubai. The mobile industry-focused event, which is now in its sixth year, will cover the key industry issues facing the region, with a particular emphasis on transformative technologies including artificial intelligence (AI), blockchain and 5G. “Mobile is having a transformative impact across this diverse region with mobile operators in the GCC states laying the foundations for leadership in 5G and planning ahead to commercial launches, while the region’s emerging markets are seeing rising smartphone adoption,” said John Giusti, Chief Regulatory Officer, GSMA. “We have a incredible line-up of expert speakers this year, ready to outline the key issues and challenges facing the region – we’re looking forward to a thought-provoking and exciting showcase.” New speakers added to the agenda include: Hakam K

Dentons Global Chairman and Global Chief Executive Officer Re-Elected19.11.2018 08:00Pressemelding

Dentons, the world's largest law firm, announced today that Joseph Andrew and Elliott Portnoy have been re-elected to three-year terms as Global Chairman and Global Chief Executive Officer, respectively. They have led the firm together since its formation in March 2013. Messrs. Andrew and Portnoy ran without opposition and have been the entrepreneurial drive and architects of Dentons’ client-centric strategy and polycentric approach to law firm management, resulting in a period of unprecedented growth while many law firms are contracting as they are buffeted by the changes shaping the legal profession globally. Under their leadership, Dentons has grown into the world’s largest law firm with more than 9,600 lawyers operating in 174 locations and 78 countries. During this same time, the firm has successfully completed dozens of business combinations throughout markets in Africa, ASEAN, Australia, Canada, Caribbean, China, Europe, Latin America, Middle East, United Kingdom and United Stat

Telefónica Deutschland Selects SIAE MICROELETTRONICA for Turn-Key DCN Migration Services in Germany19.11.2018 08:00Pressemelding

Telefónica Deutschland , a leading integrated telecommunications provider in Germany awards SIAE MICROELETTRONICA, a long-term strategic partner for wireless transmission solutions, a turn-key contract for DCN (Data Communication Networks) migration services across its backhaul network. Following the successful acquisition of E-Plus, Telefónica Deutschland new backhaul network counts over 30.000 microwave radio links from three different vendors, including SIAE MICROELETTRONICA. In preparation for a potential 5G launch in the future, Telefónica is taking steps to simplify operations and maximize performances and coherence across its network. With these activities Telefónica plans to update its DCN by implementing a new common-DCN architectural model. The migration services entrusted to SIAE MICROELETTRONICA include project- management, IP network design, new-model implementation and operation service delivery. The cluster-by-cluster migration process consists of a mix of remote configu

Biosense Webster Launches Report - The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic Across Europe19.11.2018 06:00Pressemelding

Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation (AF) has today, during AF Association Global AF Aware Week, published a report that uncovers the growing burden of AF on patients, caregivers and healthcare systems across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181118005008/en/ The new report is calling for greater awareness and emphasis on the scale and impact of AF which is fast becoming one of the world’s most significant health issues. The new millennium epidemic not only disrupts the quality of life for the 11 million people across Europe who suffer from AF, but also costs healthcare systems up to €3,286 million annually across European countries.2-7 AF is characterized by an irregular and often fast heart rhythm that results in uncoordinated contraction of the top two chambers of the heart. The irregular heart rhythm may cause blood cl

China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection19.11.2018 03:00Pressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Vemlidy® (tenofovir alafenamide, TAF) 25 mg, a once-daily treatment for chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg). Vemlidy is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 300 mg but at one-tenth of the dose. Data show that because Vemlidy has greater plasma stability and more efficiently delivers tenofovir to hepatocytes compared to Viread, it can be given at a lower dose, resulting in less tenofovir in the bloodstream. In clinical trials, Vemlidy demonstrated improved renal and bone laboratory safety parameters compared to Viread. “With the approval of Vemlidy, physicians can now offer their patients a treatment that retains the efficacy of TDF while improving renal and bone safety parameters in cli